Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 63100 | 4.5601 |
09:34 ET | 50439 | 4.5801 |
09:36 ET | 41180 | 4.59 |
09:38 ET | 101786 | 4.615 |
09:39 ET | 64890 | 4.625 |
09:41 ET | 195752 | 4.6 |
09:43 ET | 155892 | 4.6105 |
09:45 ET | 12383 | 4.6 |
09:48 ET | 31059 | 4.6002 |
09:50 ET | 97801 | 4.65 |
09:52 ET | 21300 | 4.64 |
09:54 ET | 64571 | 4.62 |
09:56 ET | 24715 | 4.62 |
09:57 ET | 58285 | 4.6401 |
09:59 ET | 82654 | 4.625 |
10:01 ET | 9720 | 4.63 |
10:03 ET | 151894 | 4.605 |
10:06 ET | 76620 | 4.61 |
10:08 ET | 20158 | 4.635 |
10:10 ET | 8966 | 4.64 |
10:12 ET | 203750 | 4.64 |
10:14 ET | 23912 | 4.64 |
10:15 ET | 37068 | 4.645 |
10:17 ET | 102058 | 4.6012 |
10:19 ET | 4562 | 4.605 |
10:21 ET | 47129 | 4.6 |
10:24 ET | 25315 | 4.5899 |
10:26 ET | 514817 | 4.59 |
10:28 ET | 39453 | 4.6 |
10:30 ET | 61720 | 4.58 |
10:32 ET | 105089 | 4.59 |
10:33 ET | 2964 | 4.585 |
10:35 ET | 11873 | 4.58 |
10:37 ET | 4739 | 4.59 |
10:39 ET | 9668 | 4.575 |
10:42 ET | 6486 | 4.58 |
10:44 ET | 14289 | 4.575 |
10:46 ET | 55688 | 4.575 |
10:48 ET | 500 | 4.58 |
10:50 ET | 14179 | 4.58 |
10:51 ET | 10252 | 4.575 |
10:53 ET | 23927 | 4.575 |
10:55 ET | 7236 | 4.576 |
10:57 ET | 8026 | 4.57 |
11:00 ET | 10884 | 4.575 |
11:02 ET | 3602 | 4.58 |
11:04 ET | 957 | 4.575 |
11:06 ET | 2129 | 4.58 |
11:08 ET | 4832 | 4.58 |
11:09 ET | 11371 | 4.575 |
11:11 ET | 3884 | 4.58 |
11:13 ET | 14302 | 4.575 |
11:15 ET | 17397 | 4.585 |
11:18 ET | 42811 | 4.594 |
11:20 ET | 2089 | 4.595 |
11:22 ET | 6900 | 4.595 |
11:24 ET | 19499 | 4.59 |
11:26 ET | 31649 | 4.585 |
11:27 ET | 22556 | 4.575 |
11:29 ET | 893 | 4.575 |
11:31 ET | 12118 | 4.57 |
11:33 ET | 2914 | 4.565 |
11:36 ET | 6525 | 4.56 |
11:38 ET | 2888 | 4.5501 |
11:40 ET | 53089 | 4.54 |
11:42 ET | 18746 | 4.53 |
11:44 ET | 16995 | 4.5391 |
11:45 ET | 3343 | 4.535 |
11:47 ET | 6914 | 4.53 |
11:49 ET | 15342 | 4.53 |
11:51 ET | 1018 | 4.525 |
11:54 ET | 8748 | 4.525 |
11:56 ET | 890 | 4.53 |
11:58 ET | 15936 | 4.535 |
12:00 ET | 1350 | 4.54 |
12:02 ET | 2581 | 4.535 |
12:03 ET | 19404 | 4.525 |
12:05 ET | 5372 | 4.52 |
12:07 ET | 14261 | 4.5197 |
12:09 ET | 24777 | 4.52 |
12:12 ET | 9135 | 4.5199 |
12:14 ET | 1346 | 4.515 |
12:16 ET | 8310 | 4.52 |
12:18 ET | 1119 | 4.525 |
12:20 ET | 13262 | 4.525 |
12:21 ET | 10977 | 4.5242 |
12:23 ET | 2048 | 4.525 |
12:25 ET | 2700 | 4.529 |
12:27 ET | 7696 | 4.54 |
12:30 ET | 2793 | 4.535 |
12:32 ET | 11115 | 4.535 |
12:34 ET | 1077 | 4.535 |
12:36 ET | 3226 | 4.535 |
12:38 ET | 155 | 4.535 |
12:39 ET | 1166 | 4.54 |
12:41 ET | 6942 | 4.535 |
12:43 ET | 44967 | 4.535 |
12:45 ET | 1361 | 4.535 |
12:48 ET | 2318 | 4.535 |
12:50 ET | 586 | 4.535 |
12:52 ET | 3663 | 4.5342 |
12:54 ET | 21475 | 4.54 |
12:56 ET | 3235 | 4.535 |
12:57 ET | 9805 | 4.54 |
12:59 ET | 3553 | 4.54 |
01:01 ET | 44947 | 4.535 |
01:03 ET | 36022 | 4.53 |
01:06 ET | 1800 | 4.535 |
01:08 ET | 1306 | 4.535 |
01:10 ET | 863 | 4.535 |
01:12 ET | 26960 | 4.535 |
01:14 ET | 7288 | 4.535 |
01:15 ET | 1100 | 4.535 |
01:17 ET | 21943 | 4.525 |
01:19 ET | 2847 | 4.525 |
01:21 ET | 9250 | 4.52 |
01:24 ET | 4070 | 4.52 |
01:26 ET | 28716 | 4.525 |
01:28 ET | 2272 | 4.52 |
01:30 ET | 89171 | 4.4988 |
01:32 ET | 24529 | 4.49 |
01:33 ET | 8269 | 4.495 |
01:35 ET | 7100 | 4.5 |
01:37 ET | 7790 | 4.495 |
01:39 ET | 10528 | 4.4995 |
01:42 ET | 17636 | 4.49 |
01:44 ET | 1715 | 4.495 |
01:46 ET | 2538 | 4.49 |
01:48 ET | 4418 | 4.495 |
01:50 ET | 1294 | 4.495 |
01:51 ET | 100 | 4.5 |
01:53 ET | 920 | 4.5 |
01:55 ET | 2069 | 4.5 |
01:57 ET | 29840 | 4.495 |
02:00 ET | 4799 | 4.505 |
02:02 ET | 3650 | 4.5077 |
02:04 ET | 11663 | 4.51 |
02:06 ET | 200 | 4.51 |
02:08 ET | 44859 | 4.5 |
02:09 ET | 6958 | 4.5 |
02:11 ET | 10312 | 4.515 |
02:13 ET | 11570 | 4.5 |
02:15 ET | 15774 | 4.495 |
02:18 ET | 617 | 4.495 |
02:20 ET | 10666 | 4.5 |
02:22 ET | 17538 | 4.4999 |
02:24 ET | 42945 | 4.495 |
02:26 ET | 17496 | 4.495 |
02:27 ET | 1950 | 4.5 |
02:29 ET | 8092 | 4.5 |
02:31 ET | 16436 | 4.4993 |
02:33 ET | 3712 | 4.4946 |
02:36 ET | 5758 | 4.5 |
02:38 ET | 13114 | 4.495 |
02:40 ET | 24574 | 4.5 |
02:42 ET | 8982 | 4.51 |
02:44 ET | 9319 | 4.515 |
02:45 ET | 4171 | 4.515 |
02:47 ET | 21687 | 4.5247 |
02:49 ET | 17497 | 4.515 |
02:51 ET | 1139 | 4.51 |
02:54 ET | 53450 | 4.505 |
02:56 ET | 30912 | 4.51 |
02:58 ET | 3346 | 4.51 |
03:00 ET | 6955 | 4.505 |
03:02 ET | 29904 | 4.505 |
03:03 ET | 130480 | 4.505 |
03:05 ET | 146839 | 4.515 |
03:07 ET | 23125 | 4.51 |
03:09 ET | 14306 | 4.535 |
03:12 ET | 11211 | 4.53 |
03:14 ET | 34522 | 4.515 |
03:16 ET | 14774 | 4.53 |
03:18 ET | 20447 | 4.52 |
03:20 ET | 11879 | 4.535 |
03:21 ET | 21267 | 4.54 |
03:23 ET | 13325 | 4.5392 |
03:25 ET | 5577 | 4.545 |
03:27 ET | 3058 | 4.545 |
03:30 ET | 8438 | 4.545 |
03:32 ET | 5574 | 4.545 |
03:34 ET | 27609 | 4.535 |
03:36 ET | 2880 | 4.535 |
03:38 ET | 6820 | 4.535 |
03:39 ET | 7764 | 4.54 |
03:41 ET | 52214 | 4.535 |
03:43 ET | 5897 | 4.53 |
03:45 ET | 3579 | 4.54 |
03:48 ET | 54333 | 4.55 |
03:50 ET | 63817 | 4.55 |
03:52 ET | 20576 | 4.547 |
03:54 ET | 19647 | 4.55 |
03:56 ET | 199154 | 4.535 |
03:57 ET | 74446 | 4.55 |
03:59 ET | 1349600 | 4.54 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.6x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.6x | --- |
Immunitybio Inc | 2.6B | -4.0x | --- |
CG Oncology Inc | 2.5B | -32.3x | --- |
IDEAYA Biosciences Inc | 2.7B | -14.5x | --- |
Structure Therapeutics Inc | 2.5B | -19.6x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.6x |
Price/Sales (TTM) | 1,993.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.